Guillain-Barré syndrome is rare, but it moves fast. It usually starts with tingling in the toes and heaviness in the legs, and within a day or two stairs become hard. Because the immune attack on peripheral nerves can climb to the muscles that drive breathing and swallowing, weakness that is worse than it was a few hours ago is a medical emergency. Anyone whose weakness is climbing both legs, especially weeks after a stomach bug or respiratory infection, should go to an emergency department rather than wait.
The condition is treatable, and treatment works better the earlier it starts. The CDC estimates that 3,000 to 6,000 Americans develop it each year, and most walk again. This guide covers the variants, the workup, and what recovery looks like.
What is Guillain-Barré syndrome?
Guillain-Barré syndrome is an acute immune-mediated polyradiculoneuropathy: the immune system mistakenly attacks the peripheral nerves and the nerve roots leaving the spinal cord, over days rather than years. Those nerves carry movement commands to muscles and sensation back, so damage produces weakness, numbness, and vanished reflexes rather than confusion or vision loss.
In the common form the target is myelin, the fatty insulation around each nerve fiber; stripped of it, a nerve conducts slowly or not at all. In the axonal variants the fiber itself is attacked. That distinction shapes recovery: myelin rebuilds in weeks, while axons regrow at roughly a millimeter a day.
It is not inherited, not contagious, and not a stroke. It is monophasic: it attacks once, reaches a floor, then repairs. One to two people per 100,000 develop it annually in the United States.
Symptoms and how they progress
Classic Guillain-Barré syndrome starts low and works upward. Pins and needles appear in the toes and fingers, then within hours to days weakness reaches the thighs, trunk, arms, and sometimes the face and throat. It is characteristically symmetric, and deep tendon reflexes disappear early. Deep aching back and thigh pain often comes first. Autonomic involvement brings blood pressure swings, an unstable heart rate, or bladder trouble. Miller Fisher cases start at the head instead.
Warning signs that require emergency care
Three developments demand an immediate emergency visit, not a phone call. The first is breathing difficulty: shortness of breath at rest, an inability to finish a sentence in one breath, or a weak cough. Up to 30 percent of patients develop respiratory failure, and the decline can be quiet and quick. The second is trouble swallowing, a wet voice, or choking. The third is visibly ascending weakness. Doctors take two-sided facial weakness seriously, because a one-sided droop usually signals Bell’s palsy, a facial nerve problem that resolves on its own in most people.
The typical timeline: progression, plateau, and recovery
The illness follows a three-phase arc. The progressive phase runs to maximum weakness, called the nadir; the National Institute of Neurological Disorders and Stroke reports that most people reach it within two weeks and 90 percent by week three. Progression beyond four weeks points to another diagnosis. A plateau follows for days to weeks. Recovery then unwinds in reverse: trunk and thigh strength return before hands and feet, over months rather than days.
Variants of Guillain-Barré syndrome
This is a family of related conditions rather than one disease, sharing an abrupt immune attack on peripheral nerves but differing in which component is hit.
| Variant | What is affected | Distinguishing feature |
|---|---|---|
| AIDP (acute inflammatory demyelinating polyradiculoneuropathy) | Myelin on motor and sensory nerves | Dominant form in North America; slowed conduction with numbness |
| AMAN (acute motor axonal neuropathy) | Motor nerve fibers, sensation spared | Pure weakness; often follows Campylobacter infection |
| AMSAN (acute motor-sensory axonal neuropathy) | Motor and sensory nerve fibers | Most severe subtype; slower, less complete recovery |
| Miller Fisher syndrome | Cranial nerves for eye movement and coordination | Eye movement paralysis, unsteady gait; anti-GQ1b antibodies |
Causes and triggers
About two out of three patients had diarrhea or a respiratory infection in the preceding weeks. The explanation is molecular mimicry: some microbes carry surface sugars resembling molecules on nerve membranes, so antibodies built against the infection cross-react with the nerves.
The most common trigger is Campylobacter jejuni, a foodborne bacterium that causes a bout of gastroenteritis that usually settles a week or two before the weakness begins. The absolute risk stays tiny: about one in 1,000 Campylobacter infections is followed by it. Surveillance studies also implicate the influenza virus that circulates across the United States every winter. Cytomegalovirus, Epstein-Barr virus, Mycoplasma, hepatitis E, Zika, and SARS-CoV-2 are linked too, as are surgery and some cancer immunotherapies.
Vaccines deserve a direct answer: the association is real, small, and misrepresented in both directions. The 1976 swine flu campaign produced about one extra case per 100,000 people vaccinated. For modern seasonal flu vaccines, in seasons where any increase is detected, the CDC puts it at one to two extra cases per million doses, against a background rate of one to two cases per 100,000 people per year. Influenza itself can trigger the syndrome, and the CDC’s conclusion is that a person is more likely to develop it after catching the flu than after the flu shot. COVID-19 vaccines follow the same shape: a small increase confined to adenovirus-vectored products, none for messenger RNA vaccines. None of this argues for skipping vaccination, because the infections vaccines prevent are the larger trigger.
How Guillain-Barré syndrome is diagnosed
No single test confirms it. Diagnosis rests on the clinical picture: rapidly progressing, symmetric weakness in more than one limb with reduced or absent reflexes over days to four weeks. Absent reflexes in a weak limb steer clinicians away from a spinal cord lesion, where reflexes stay brisk. Neurologists also consider myasthenia gravis, a disorder of the nerve-muscle junction that produces fluctuating weakness and drooping eyelids, plus cord compression and botulism.
Nerve conduction studies send electrical pulses along a nerve and time the response, showing whether signals travel slowly, as in demyelination, or arrive on schedule but weakened, as in axonal damage. Electromyography records muscle activity through a fine needle. Both are often normal in the first days, so an early normal result does not overturn the clinical picture.
A lumbar puncture is the third pillar. The spinal fluid classically shows albuminocytologic dissociation: raised protein with a normal white cell count. Inflamed roots leak protein, while the normal cell count argues against meningitis. This pattern appears in only half of patients during week one, far more by weeks two and three.
The blood tests that matter and what they rule in or out
Bloodwork does not diagnose the condition; it excludes imitators. It includes a complete blood count that helps exclude infection and severe anemia as explanations for the weakness. Electrolyte panels measure a potassium level that can itself produce sudden, profound weakness when it drops far enough, and they catch low sodium. Clinicians often order C-reactive protein, a blood marker that climbs during active infection and inflammation. Serology can identify Lyme disease, a tick-borne infection that inflames nerve roots and cranial nerves in some patients. Antiganglioside antibodies, notably anti-GQ1b, are sent when Miller Fisher is suspected.
Treatment options
Two immune treatments have solid randomized evidence and are equally effective when started within two weeks of onset. Intravenous immunoglobulin, or IVIG, delivers pooled donor antibodies over about five days, neutralizing autoantibodies and dampening complement activation. Plasma exchange filters the blood across roughly five sessions, removing the plasma carrying those antibodies. The choice is practical: IVIG needs only an intravenous line. Combining them adds nothing.
Supportive care determines survival as much as immunotherapy. Vital capacity is measured repeatedly, and patients whose numbers fall are intubated before a crisis rather than after. Cardiac monitoring catches the arrhythmias of autonomic instability, blood thinners prevent clots, and swallowing assessment prevents aspiration. Corticosteroids are the notable exception: randomized trials in the 1970s and 1980s found no benefit, and oral steroids may slow recovery. They are not recommended, which surprises patients who link steroids with every autoimmune disease.
Recovery and rehabilitation
Rehabilitation begins in the hospital bed. Passive range-of-motion work protects joints, careful positioning prevents pressure injuries, and breathing exercises maintain lung volume. As strength returns, therapy advances from bed mobility to sitting balance to supported walking, while occupational therapy targets buttons, keys, and jar lids.
Fatigue most often blindsides people, and pacing beats pushing. A systematic review of exercise programs in this syndrome and in CIDP found that supervised, individualized training combining resistance, aerobic, balance, and breathing work improves fatigue and functional capacity, with the best results from 45- to 60-minute sessions three to four times weekly beyond 12 weeks (De León-Muñoz et al., 2025). Teams also recheck vitamin B12 levels that slow peripheral nerve repair when they run low. Neuropathic pain often outlasts the weakness, and depression deserves screening.
Long-term outlook
Most people recover well. Acute-phase mortality is under 2 percent in well-resourced hospitals, and roughly 80 percent walk independently again within six months.
Honesty requires the rest of the picture. Recovery is often incomplete: Cleveland Clinic reports that about 30 percent of adults still have residual muscle weakness three years after diagnosis, typically foot drop, weak ankles, or persistent numbness in the feet. Fatigue is the most reported long-term symptom and can persist for years after strength tests look normal. Older age, rapid progression, preceding diarrheal illness, and axonal damage predict a rougher course. Recurrence affects roughly 2 to 5 percent, and a small group worsening past eight weeks is reclassified as having chronic inflammatory demyelinating polyneuropathy.
Latest scientific advances
Complement, a cascade of blood proteins that antibodies recruit to destroy their targets, drives much of this nerve damage, so researchers tested whether blocking it helps. A phase 3, double-blind randomized trial in Japan gave 57 adults with severe disease either eculizumab, which blocks the complement protein C5, or placebo, both on top of IVIG. It worked biologically, cutting free C5 in the blood by 99.99 percent within an hour, but did not speed recovery: time to regain the ability to run matched placebo (hazard ratio 0.9, 95% confidence interval 0.45 to 1.97, p = 0.89), and no secondary endpoint reached significance (Kuwabara et al., 2024). What this means for you: complement blockade remains unproven, so IVIG or plasma exchange is what your team should reach for today.
A second study addressed the question patients ask constantly: how long will this take? Researchers measured serum neurofilament light chain, a protein that leaks from damaged nerve fibers into the blood and so gauges axonal injury, in 281 patients from a randomized IVIG trial. High levels at two weeks were strongly associated with being unable to walk unaided at four weeks (odds ratio 1.74, 95% CI 1.27 to 2.45), and high levels at four weeks predicted the same at 26 weeks (odds ratio 2.79, 95% CI 1.72 to 4.90), adding value beyond the established clinical score (van Tilburg et al., 2024). What this means for you: a blood test that forecasts your recovery timeline is nearing the clinic.
The vaccine question got a rigorous answer too. A meta-analysis pooled 15 cohort studies of Guillain-Barré syndrome after COVID-19 vaccination. Across all vaccine types the pooled rate was 1.25 cases per million doses. By technology, adenovirus-vectored vaccines showed 3.93 cases per million doses and a 2.37-fold increase in risk, while messenger RNA vaccines showed 0.69 per million and no increase at all (Censi et al., 2024). What this means for you: the association is real but confined to one platform and vanishingly rare, so discuss platform choice with your clinician rather than skip vaccination.
Myths and facts
Myth: it is contagious. Fact: it is not. The syndrome is your own immune system misfiring after an infection has resolved. The triggering infection may have been contagious; this is not.
Myth: vaccines cause it. Fact: infections cause the overwhelming majority of cases. A small increase has been measured for a few vaccines, roughly one to two extra cases per million flu doses, against a larger risk from the infections they prevent.
Myth: steroids are standard treatment because it is autoimmune. Fact: randomized trials showed no benefit. IVIG and plasma exchange are the evidence-based options.
Glossary
| Term | What it means |
|---|---|
| Polyradiculoneuropathy | Damage to peripheral nerves and the nerve roots leaving the spinal cord |
| Myelin | The fatty sheath around nerve fibers that lets signals travel quickly |
| Axon | The long fiber of a nerve cell; regrows far slower than myelin repairs |
| Albuminocytologic dissociation | Spinal fluid with high protein but a normal white cell count |
| Nadir | The point of maximum weakness, after which the illness plateaus |
| IVIG | Intravenous immunoglobulin, pooled donor antibodies that blunt the immune attack |
| Neurofilament light chain | A protein released by injured nerve fibers, measurable in blood |
Frequently asked questions
What are the first signs of Guillain-Barré syndrome?
The earliest signs are tingling or numbness in the toes and fingertips, often with deep aching back or thigh pain. Weakness follows within hours to days, starting in the legs and climbing upward, affecting both sides equally. Stairs become difficult, then flat ground, and reflexes fade early. Many people had a stomach bug or respiratory infection weeks earlier. Because progression is rapid, these symptoms need same-day emergency care.
What causes Guillain-Barré syndrome?
An infection precedes about two-thirds of cases. The immune system builds antibodies against a microbe whose surface molecules resemble structures on peripheral nerves, and once the infection clears those antibodies attack the nerves instead. Campylobacter food poisoning is the most commonly identified trigger, followed by influenza, cytomegalovirus, Epstein-Barr virus, Mycoplasma, hepatitis E, and Zika. Surgery and cancer immunotherapies are rarer, and vaccines account for a very small fraction.
How long does it take to recover from Guillain-Barré syndrome?
Recovery is measured in months. Weakness peaks within two to four weeks, plateaus, then improves in reverse order, with trunk and thigh strength returning before hand and foot function. Mild cases often resolve within three to six months, while people who needed a ventilator work at it for a year or longer. Around 80 percent walk independently again by six months, though fatigue can linger well beyond that.
Is Guillain-Barré syndrome fatal?
It can be, which is why it is treated as an emergency, but death is uncommon with modern care. Fewer than 2 percent of patients die during the acute phase in well-equipped hospitals. The danger comes from respiratory failure, affecting up to 30 percent, and from autonomic instability causing dangerous heart rhythm and blood pressure swings. Both are manageable where intensive care is available.
Can Guillain-Barré syndrome come back?
Recurrence is uncommon. Most people have a single episode, because the illness is monophasic by definition: it attacks once, reaches a nadir, then repairs. Roughly 2 to 5 percent experience a second episode, higher than the general population risk but still low. Separately, a small group deteriorates or relapses beyond eight weeks, and those patients are reclassified as having chronic inflammatory demyelinating polyneuropathy.
Sources
- National Institute of Neurological Disorders and Stroke — Guillain-Barré Syndrome — NIH, 2025 — ninds.nih.gov
- MedlinePlus — Guillain-Barré Syndrome — National Library of Medicine, 2025 — medlineplus.gov
- Centers for Disease Control and Prevention — Guillain-Barré Syndrome and Vaccines — CDC, 2024 — cdc.gov
- Cleveland Clinic — Guillain-Barré Syndrome — Cleveland Clinic, 2025 — clevelandclinic.org
- GBS/CIDP Foundation International — Guillain-Barré Syndrome — GBS/CIDP Foundation, 2025 — gbs-cidp.org
- Kuwabara S et al. — Eculizumab in Guillain-Barré Syndrome — Journal of the Peripheral Nervous System, 2024 — doi.org
- van Tilburg SJ et al. — Serum Neurofilament Light Chain in Guillain-Barré Syndrome — EBioMedicine, 2024 — doi.org
- Censi S et al. — Guillain-Barré Syndrome and COVID-19 Vaccination — Journal of Neurology, 2024 — doi.org
Further reading
- Readers comparing autoimmune conditions that damage myelin often want to understand multiple sclerosis, a central nervous system disease that attacks myelin inside the brain and spinal cord.
- Anyone whose nerve symptoms arrive alongside rashes and joint pain should review lupus, a systemic autoimmune disease that can involve the nervous system as well as skin and joints.
- Families curious about how this differs from historical paralytic illness can explore polio, a viral infection that once caused sudden limb paralysis in children.
- Anyone handed an abnormal autoimmune screen should review antinuclear antibody results that point toward a systemic autoimmune disease.
Understand your lab results with BloodSense
Bloodwork does not diagnose Guillain-Barré syndrome, but it shapes almost every decision around it. The initial workup pairs a complete blood count with electrolytes, kidney and liver panels, glucose, thyroid tests, and inflammatory markers. Those results exclude low potassium, low sodium, thyroid disease, vitamin B12 deficiency, and Lyme disease, all of which imitate rapid-onset weakness. Monitoring continues through recovery: sodium is rechecked, kidney function watched during IVIG, and blood counts followed during plasma exchange.
If your results arrived as a page of numbers, BloodSense reads your uploaded report, explains what each marker measures, flags values outside the reference range, and puts the panel into plain language for your next appointment.
